Last reviewed 2026-04-23 · How we verify

VDCLD regimen

The VDCLD regimen is a combination of chemotherapy drugs used to treat various types of cancer.

The VDCLD regimen is a combination of chemotherapy drugs used to treat various types of cancer. Used for Non-small cell lung cancer, Small cell lung cancer, Head and neck cancer.

At a glance

Mechanism of action

The exact mechanism of action of the VDCLD regimen is not well understood, but it is believed to work by targeting rapidly dividing cancer cells and inhibiting their growth. The regimen is a combination of multiple drugs, each with its own mechanism of action, which together provide a synergistic effect to treat cancer.

Approved indications

• Non-small cell lung cancer
• Small cell lung cancer
• Head and neck cancer
• Esophageal cancer
• Gastric cancer
• Breast cancer
• Colorectal cancer
• Pancreatic cancer
• Gastrointestinal stromal tumor

Common side effects

• Neutropenia
• Thrombocytopenia
• Anemia
• Nausea and vomiting
• Diarrhea
• Fatigue
• Mucositis

Key clinical trials

• Comparison of Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen in the Treatment of Adult ALL Patients
• Pegylated Liposomal Doxorubicin Versus Daunorubicin to Treat Acute Lymphoblastic Leukemia: (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• VDCLD regimen CI brief — competitive landscape report
• VDCLD regimen updates RSS · CI watch RSS
• Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. portfolio CI